Your browser doesn't support javascript.
loading
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Caban, Monika; Koblmueller, Bettina; Groza, Diana; Schueffl, Hemma H; Terenzi, Alessio; Tolios, Alexander; Mohr, Thomas; Mathuber, Marlene; Kryeziu, Kushtrim; Jaunecker, Carola; Pirker, Christine; Keppler, Bernhard K; Berger, Walter; Kowol, Christian R; Heffeter, Petra.
Afiliação
  • Caban M; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Koblmueller B; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Groza D; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Schueffl HH; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Terenzi A; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Italy.
  • Tolios A; Department of Transfusion Medicine and Cellular Therapy, Institute of Vascular Biology, Medical University of Vienna, AT-1090, Vienna, Austria; Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Austria.
  • Mohr T; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Mathuber M; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Kryeziu K; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Jaunecker C; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Pirker C; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Keppler BK; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Berger W; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Kowol CR; Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria.
  • Heffeter P; Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria; Research Cluster "Translational Cancer Therapy Research", University of Vienna and Medical University of Vienna, Austria. Electronic address: petra.heffeter@meduniwien.ac.at.
Cancer Lett ; 565: 216237, 2023 07 01.
Article em En | MEDLINE | ID: mdl-37211067
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pró-Fármacos / Neoplasias Pulmonares / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article